Dr. Reddy's Looks To Acquire U.S. Generics Company Following $115 Mil. IPO
Executive Summary
Dr. Reddy's Laboratories plans to expand its presence in the U.S. generics market through acquisitions following its April 11 initial public offering.
You may also be interested in...
Par Aims To Add Branded Products After Merck KGaA Divests Equity Stake
Par is looking to add branded products to its portfolio as it seeks to join the top-tier independent generic drug companies after Merck KGaA divests its controlling interest in the firm.
Par Aims To Add Branded Products After Merck KGaA Divests Equity Stake
Par is looking to add branded products to its portfolio as it seeks to join the top-tier independent generic drug companies after Merck KGaA divests its controlling interest in the firm.
Par Generic Fluoxetine Expected To Launch In Three Strengths On Aug. 2
Par plans to launch 10 mg, 20 mg and 40 mg strengths of fluoxetine Aug. 2 following the expiry of Lilly's pediatric exclusivity for Prozac.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: